Previously submitted to: Journal of Medical Internet Research (no longer under consideration since Nov 09, 2021)
Date Submitted: Oct 25, 2021
Open Peer Review Period: Oct 25, 2021 - Nov 9, 2021
(closed for review but you can still tweet)
NOTE: This is an unreviewed Preprint
Warning: This is a unreviewed preprint (What is a preprint?). Readers are warned that the document has not been peer-reviewed by expert/patient reviewers or an academic editor, may contain misleading claims, and is likely to undergo changes before final publication, if accepted, or may have been rejected/withdrawn (a note "no longer under consideration" will appear above).
Peer review me: Readers with interest and expertise are encouraged to sign up as peer-reviewer, if the paper is within an open peer-review period (in this case, a "Peer Review Me" button to sign up as reviewer is displayed above). All preprints currently open for review are listed here. Outside of the formal open peer-review period we encourage you to tweet about the preprint.
Citation: Please cite this preprint only for review purposes or for grant applications and CVs (if you are the author).
Final version: If our system detects a final peer-reviewed "version of record" (VoR) published in any journal, a link to that VoR will appear below. Readers are then encourage to cite the VoR instead of this preprint.
Settings: If you are the author, you can login and change the preprint display settings, but the preprint URL/DOI is supposed to be stable and citable, so it should not be removed once posted.
Submit: To post your own preprint, simply submit to any JMIR journal, and choose the appropriate settings to expose your submitted version as preprint.
Warning: This is an author submission that is not peer-reviewed or edited. Preprints - unless they show as "accepted" - should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information.
Direct-to-consumer Telemedicine Platforms in China: A National Market Survey and Quality Evaluation
ABSTRACT
Background:
Direct to Consumer (DTC) telemedicine platforms are digital platforms that enable patients to match with and initiate online consultations. This growing area of digital health has the potential to expand access to quality outpatient care by extending patient choice of providers and providers’ ability to interact with new patients online.
Objective:
This study aims to to evaluate the status of DTC telemedicine and the quality of care provided through these platforms in China, the country where DTC telemedicine has expanded most rapidly.
Methods:
In this cross-sectional study, we first conducted a systematic search of all DTC telemedicine platforms in China providing on-demand consultations through video or SMS/MMS and manually scraped information from each platform. We then evaluated the quality of care provided using unannounced virtual visits by standardized patients (SPs) presenting seven different disease cases. We evaluate the performance of online providers relative to national standards of care and to traditional on-site providers in rural areas. Multiple regressions were used to assess associations between quality and platform characteristics.
Results:
The systematic search identified 36 independent platforms providing synchronous or asynchronous consultations via videoconferencing or SMS/MMS text. Platforms varied widely in design, access methods, services, and pricing. The quality of care provided through online-only platforms was superior to platforms that were extensions of physical hospitals in terms of diagnosis and case management. SPs were significantly more likely to be correctly managed through videoconference compared to SMS/MMS consultations, though costs were significantly higher. Both videoconference and SMS/MMS consultations were likely to refer patients unnecessarily. Platform features and the price of consultations were significantly associated with measures of quality.
Conclusions:
There was substantial variation in the design of DTC telemedicine platforms in China as well as the quality of care provided. Incentives inherent in the design of these platforms may influence care quality and patient costs. The expansion of DTC telemedicine may improve access to high quality care, but could increase unnecessary care and reduce equity in access without thoughtful regulation. Research is needed to inform policies governing DTC telemedicine platforms, particularly in middle-income countries such as China.
Citation
Request queued. Please wait while the file is being generated. It may take some time.
Copyright
© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.